Advertise
NEWSLETTER
Serina advances SER-252 Par...
FDA accepts review for Nano...
MetaVia data show DA-1726 c...
Coya’s combination dr...
Alzheon reports Phase 3 win...
Serina advances SER-252 Par...
FDA accepts review for Nano...
MetaVia data show DA-1726 c...
Coya’s combination dr...
Alzheon reports Phase 3 win...
Drugs

Gerostate Alpha: “Our phenotype is lifespan”

Longevity companies to watch in 2021

Senolytic start-up gears up for clinical trials

Rubedo’s first target is respiratory disease, with COVID-19 expected to drive an increase in lung disease

Juvenesence's Greg Bailey on transformative scientific opportunities, immuno-resilience and modifying aging.

Juvenescence (1): from strength to strength in R&D and investment firepower

A year in Longevity: different perspectives

A year in Longevity: founders’ perspectives

A year in Longevity: science perspectives

VC and drug developer scale-up their incubator model

Sigilon IPO raises $145m to address chronic diseases

Kristen Fortney - BioAge

BioAge CEO: “It’s all about the data.”

Silicon Valley is waking up to Longevity and senolytics

BioAge lands $90 million; gears up for clinical trials in 2021

Why government must unlock biotech’s potential to maximise Longevity

Inflammaging biotech acquired by Roche for €380m

ARDD 2020: Addressing the challenges in drug discovery

Juvenescence (2): “It’s all about prevention, and that’s incredibly disruptive”

SENISCA seeks funding for senescence reversal

Longevity investment: Apollo aims for the moon

Leading academic “profoundly disappointed” by COVID-19 response

Life Biosciences

Life Biosciences in-licenses IP from new studies

Eye

Drusolv targets macular degeneration with statin therapy

CohBar CEO on the development of a “true portfolio” of mitochondria based therapeutics for the treatment of chronic and age-related diseases.

It’s time to sit up and take notice of mitochondria

Financing led by Column Group and Lux Capital will aim to to accelerate neurodegeneration drug discovery by enabling target discovery and validation at unprecedented scale.

Unlocking the Longevity potential of our oceans

Biotech AgeX Therapeutics reported financial and commercialises its stem cell lines, but continues to borrow from stakeholder Juvenescence.

G3 and Juvenescence partner on deep learning venture

Spineless mouse

New Buck Institute study is treasure trove for longevity research

Making the Longevity grade: expanded list of 1000 leading names

Longevity Escape Velocity within 10 years?

Stanford study finds that blocking certain interactions on immune cells reverses age-related mental decline in older mice. Photography by Steve Fisch

“Adjust the immune system… de-age the brain”

Senescent cell

AI to quantify senescent cell counts

Singapore-based Gero is the brainchild of Peter Fedichev and are raising $10 million for Longevity drug discovery and indication expansion

Applying theoretical physics to Longevity drug discovery

Alex Zhavoronkov is pushing for us to examine how and when to classifying aging and how it should be implemented to overcome "inherent challenges"

Classifying aging as a disease – it’s all about the ‘how’

CohBar and NIAID announce that they are set to assess CB5064 Analogues for COVID-19 and respiratory distress treatment.

CohBar announces preclinical collaboration with NIAID

“The major modulators of aging remain to be discovered”

Kevin Perrott, co-founder of SENS and Oisin Biotechnologies, is now CEO of OpenCures focussing on developing interventions in age-related disease

Longevity and the art of motorcycle maintenance

Longevity supplement Mitocholine addresses “brain energy gap” to counteract development of metabolic syndrome and impede onset of dementia.

New Longevity supplement targets cognitive decline

Cellular senescence is currently an inevitable process, but new evidence brings an alternative splicing mechanism back to light.

Senescence and the return of established splicing tech

A year in Longevity: progress perspectives

A drug that exterminates senescent cells improves recovery after a heart attack according to new research, and could pave the way for a new heart attack treatment.

Eliminating senescent cells to improve heart attack recovery

Epigenetic aging clock DeepMAge has 3-year error margin and could be the most accurate DNA methylation clock to date.

Deep Longevity reveals highly-accurate aging clock

Calico’s memory-enhancing drug reverses age-related mental decline

Margaretta Colangelo

Margaretta Colangelo on Longevity2020

The latest longevity science, investment, innovation and insight, delivered every morning.

This field is hidden when viewing the form